Key Insights on Gross Profit: Merck & Co., Inc. vs Alnylam Pharmaceuticals, Inc.

Merck vs Alnylam: A Decade of Financial Evolution

__timestampAlnylam Pharmaceuticals, Inc.Merck & Co., Inc.
Wednesday, January 1, 20145056100025469000000
Thursday, January 1, 20154109700024564000000
Friday, January 1, 20164715900025916000000
Sunday, January 1, 20177654500027347000000
Monday, January 1, 20187310600028785000000
Tuesday, January 1, 201919468800032728000000
Wednesday, January 1, 202041480100027900000000
Friday, January 1, 202170414300035078000000
Saturday, January 1, 202286860100041872000000
Sunday, January 1, 2023151788600043989000000
Monday, January 1, 20241924873000
Loading chart...

Unlocking the unknown

A Tale of Two Giants: Merck & Co., Inc. vs Alnylam Pharmaceuticals, Inc.

In the ever-evolving landscape of pharmaceuticals, the financial performance of companies can offer a glimpse into their strategic prowess. Over the past decade, Merck & Co., Inc. has consistently demonstrated its dominance, with gross profits soaring by approximately 72% from 2014 to 2023. In contrast, Alnylam Pharmaceuticals, Inc., a rising star in the biotech sector, has seen its gross profits increase by an impressive 2,900% during the same period, albeit from a much smaller base.

Key Insights

  • Merck's Steady Growth: With gross profits peaking at $44 billion in 2023, Merck's robust pipeline and strategic acquisitions have solidified its position as a market leader.
  • Alnylam's Rapid Ascent: Despite starting with modest figures, Alnylam's innovative RNAi therapeutics have propelled its gross profits to $1.5 billion in 2023, showcasing its potential to disrupt the industry.

This financial narrative underscores the dynamic nature of the pharmaceutical industry, where established giants and innovative newcomers coexist, each shaping the future of healthcare in their unique ways.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025